News | December 15, 2022
LG Chem inks deal with Innovent Biologics for gout treatment candidate
LG Chem will receive totaling up to $95.5 million for the China rights
LG Chem will receive totaling up to $95.5 million for the China rights
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
Approval to dramatically change CAR-T therapies landscape
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
FortePhest is developing a new technology to combat herbicide-resistant weeds and invasive plants
Subscribe To Our Newsletter & Stay Updated
